

Appendix: Tables

1.	Sales January to December 2022 and 2021	2
2.	Quarterly sales and constant exchange rate sales growth by Division in 2022 and 2021	3
3.	Product sales Pharmaceuticals Division and constant exchange rate growth YTD December 2022 vs. YTD December 2021	4
4.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth	6
5.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth United States	7
6.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Europe	8
7.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Japan	9
8.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth International	10
9.	Roche Group consolidated income statement for the twelve months ended 31 December 2022	11
10.	Roche Group core results reconciliation – Full Year 2022	12
11.	Divisional core results reconciliation – Full Year 2022	13
12.	Roche Group consolidated balance sheet	14
13.	Roche Group consolidated statement of cash flows.....	15

1. Sales January to December 2022 and 2021

CHF millions	Twelve months ended 31 December		% change	
	2022	2021	At CER	In CHF
Pharmaceuticals Division	45,551	45,041	2	1
United States	23,322	22,505	-1	4
Europe	8,143	8,876	-2	-8
Japan	4,949	4,506	26	10
International*	9,137	9,154	1	0
Diagnostics Division	17,730	17,760	3	0
Roche Group	63,281	62,801	2	1

* Asia-Pacific, CEETRIS (Central Eastern Europe, Türkiye, Russia and Indian Sub-Continent), Latin America, Middle East, Africa, Canada, others

2. Quarterly sales and constant exchange rate sales growth by Division in 2022 and 2021

CHF millions	Q4 2021	% change vs. Q4 2020	Q1 2022	% change vs. Q1 2021	Q2 2022	% change vs. Q2 2021	Q3 2022	% change vs. Q3 2021	Q4 2022	% change vs. Q4 2021
Pharmaceuticals Div.	11,662	14	11,159	6	11,188	0	10,842	-6	12,362	9
United States	5,798	8	5,489	2	5,874	1	5,836	-6	6,123	1
Europe	2,266	19	2,072	-1	2,032	-6	1,996	4	2,043	-3
Japan	1,320	46	1,337	69	865	3	827	-27	1,920	69
International*	2,278	9	2,261	0	2,417	4	2,183	-3	2,276	4
Diagnostics Division	4,455	8	5,286	24	4,662	0	3,900	-4	3,882	-9
Roche Group	16,117	12	16,445	11	15,850	0	14,742	-6	16,244	4

* Asia-Pacific, CEETRIS (Central Eastern Europe, Türkiye, Russia and Indian Sub-Continent), Latin America, Middle East, Africa, Canada, others

3. Product sales Pharmaceuticals Division and constant exchange rate growth YTD December 2022 vs. YTD December 2021

CHF millions	Total		United States		Europe		Japan		International*	
	CHF m	%	CHF m	%	CHF m	%	CHF m	%	CHF m	%
Ocrevus	6,036	17	4,487	14	1,075	25	-	-	474	35
Perjeta	4,087	5	1,533	4	871	-16	234	0	1,449	27
Hemlibra	3,823	27	2,316	22	741	30	377	18	389	65
Tecentriq	3,717	14	1,975	12	794	20	443	-2	505	30
Actemra/RoActemra	2,701	-22	1,196	-35	802	-6	342	2	361	-28
Xolair	2,208	9	2,208	9	-	-	-	-	-	-
Herceptin	2,142	-19	476	-28	422	-17	51	-28	1,193	-15
Avastin	2,122	-28	634	-34	193	-52	490	-17	805	-20
Kadcyla	2,080	7	820	-3	671	5	131	16	458	34
MabThera/Rituxan	2,075	-20	1,316	-19	204	-19	32	-14	523	-24
Ronapreve	1,679	17	-	-	101	-85	1,480	163	98	-62
Alecensa	1,513	15	453	18	292	5	228	6	540	23
Activase/TNKase	1,177	-14	1,114	-15	-	-	-	-	63	9
Evrysdi	1,119	87	470	23	353	236	84	406	212	89
Lucentis	1,012	-28	1,012	-28	-	-	-	-	-	-
Phesgo	740	121	304	93	367	142	-	-	69	156
Gazyva	730	9	345	5	192	-8	50	-8	143	81
Esbriet	718	-31	455	-41	234	-7	-	-	29	-15
Vabysmo	591	-	517	-	22	-	47	-	5	-
Pulmozyme	543	-5	369	-3	96	-12	1	23	77	-4
Polivy	437	85	165	72	132	68	113	127	27	101
Erivedge	271	1	173	0	58	3	-	-	40	23

Enspryng	192	93	54	122	9	253	122	73	7	498
Rozlytrek	75	51	47	40	12	75	7	28	9	156
Xofluza	67	**	52	**	-	-	-	-	15	456
Cotellic	48	-3	14	1	15	-8	-	-	19	-1
Gavreto	26	175	22	133	4	**	-	-	-	-
Lunsumio	3	-	-	-	3	-	-	-	-	-
Susvimo	2	75	2	75	-	-	-	-	-	-
Pharma other	3,617	-13	793	-19	480	-14	717	-11	1,627	-10
Pharma total sales	45,551	2	23,322	-1	8,143	-2	4,949	26	9,137	1

* Asia-Pacific, CEETRIS (Central Eastern Europe, Türkiye, Russia and Indian Sub-Continent), Latin America, Middle East, Africa, Canada, others

** Over 500%

4. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth

CHF millions	Q4 2021	% change vs. Q4 2020	Q1 2022	% change vs. Q1 2021	Q2 2022	% change vs. Q2 2021	Q3 2022	% change vs. Q3 2021	Q4 2022	% change vs. Q4 2021
Ocrevus	1,334	25	1,449	18	1,461	17	1,517	16	1,609	18
Perjeta	981	3	993	1	1,068	9	1,029	5	997	4
Hemlibra	850	38	853	30	973	31	952	23	1,045	24
Tecentriq	838	17	825	8	933	13	934	9	1,025	24
Actemra/RoActemra	872	21	792	3	663	-23	584	-42	662	-22
Xolair	526	14	456	9	569	13	600	8	583	6
Herceptin	633	-6	607	-19	572	-11	493	-23	470	-22
Avastin	666	-30	581	-32	561	-27	510	-28	470	-25
Kadcyla	522	16	511	9	563	18	516	6	490	-3
MabThera/Rituxan	597	-26	564	-21	553	-20	479	-19	479	-20
Ronapreve	546	-	587	272	22	-91	22	-92	1,048	118
Alecensa	368	15	361	23	384	16	382	11	386	10
Activase/TNKase	391	22	247	-20	312	1	322	-5	296	-27
Evrysdi	206	347	226	189	274	65	293	93	326	59
Lucentis	336	2	256	-26	316	-9	228	-39	212	-40
Phesgo	127	*	146	410	179	168	201	76	214	73
Gazyva	177	10	165	7	184	9	190	9	191	9
Esbriet	250	-7	241	-6	216	-21	133	-48	128	-48
Vabysmo	-	-	21	-	88	-	173	-	309	-
Pulmozyme	152	5	136	-3	143	2	135	-3	129	-15

* Over 500%

5. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth United States

CHF millions	Q4 2021	% change vs. Q4 2020	Q1 2022	% change vs. Q1 2021	Q2 2022	% change vs. Q2 2021	Q3 2022	% change vs. Q3 2021	Q4 2022	% change vs. Q4 2021
Ocrevus	998	23	1,050	12	1,090	10	1,143	17	1,204	15
Perjeta	337	-2	362	-1	378	4	395	0	398	13
Hemlibra	498	33	520	28	578	24	586	16	632	21
Tecentriq	416	2	446	10	505	15	500	3	524	20
Actemra/RoActemra	461	67	380	22	284	-31	250	-61	282	-42
Xolair	526	14	456	9	569	13	600	8	583	6
Herceptin	135	-34	144	-26	119	-29	113	-29	100	-29
Avastin	177	-45	178	-39	164	-36	155	-31	137	-26
Kadcyla	200	3	204	0	211	-1	204	-8	201	-4
MabThera/Rituxan	355	-32	347	-20	344	-24	311	-14	314	-15
Ronapreve	-	-	-	-	-	-	-	-	-	-
Alecensa	103	18	99	25	108	14	124	22	122	13
Activase/TNKase	376	22	234	-21	297	1	305	-6	278	-29
Evrysdi	97	112	109	36	118	28	121	13	122	20
Lucentis	336	2	256	-26	316	-9	228	-39	212	-40
Phesgo	53	236	60	187	78	134	79	62	87	58
Gazyva	81	11	75	0	86	3	90	7	94	11
Esbriet	176	-7	170	-4	143	-28	68	-67	74	-60
Vabysmo	-	-	21	-	80	-	152	-	264	-
Pulmozyme	101	6	87	0	97	5	96	2	89	-17

* Over 500%

6. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Europe

CHF millions	Q4 2021	% change vs. Q4 2020	Q1 2022	% change vs. Q1 2021	Q2 2022	% change vs. Q2 2021	Q3 2022	% change vs. Q3 2021	Q4 2022	% change vs. Q4 2021
Ocrevus	227	26	280	34	259	34	269	11	267	26
Perjeta	265	-8	228	-21	229	-12	204	-15	210	-15
Hemlibra	169	53	170	31	190	29	182	36	199	27
Tecentriq	193	41	183	14	200	24	190	17	221	23
Actemra/RoActemra	252	18	220	-4	200	-2	182	-3	200	-14
Xolair	-	-	-	-	-	-	-	-	-	-
Herceptin	137	-3	122	-13	111	-9	96	-18	93	-27
Avastin	84	-49	58	-56	58	-49	42	-47	35	-56
Kadcyla	179	16	172	8	178	12	158	3	163	-2
MabThera/Rituxan	65	-13	54	-19	51	-16	51	-18	48	-21
Ronapreve	159	-	62	-61	3	-99	37	-54	-1	-100
Alecensa	76	9	75	5	74	8	69	5	74	3
Activase/TNKase	-	-	-	-	-	-	-	-	-	-
Evrysdi	51	*	68	*	84	227	101	216	100	116
Lucentis	-	-	-	-	-	-	-	-	-	-
Phesgo	71	-	76	*	87	188	100	107	104	61
Gazyva	56	2	46	-5	49	-8	49	-9	48	-8
Esbriet	67	0	62	-5	65	1	59	1	48	-23
Vabysmo	-	-	-	-	-	-	4	-	18	-
Pulmozyme	28	-15	26	-11	25	-12	22	-12	23	-13

* Over 500%

7. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Japan

CHF millions	Q4 2021	% change vs. Q4 2020	Q1 2022	% change vs. Q1 2021	Q2 2022	% change vs. Q2 2021	Q3 2022	% change vs. Q3 2021	Q4 2022	% change vs. Q4 2021
Ocrevus	-	-	-	-	-	-	-	-	-	-
Perjeta	68	-3	59	-1	61	-1	55	-1	59	3
Hemlibra	105	30	84	15	96	24	97	22	100	14
Tecentriq	131	34	107	-5	111	-9	108	0	117	6
Actemra/RoActemra	97	5	87	12	87	-2	82	-4	86	6
Xolair	-	-	-	-	-	-	-	-	-	-
Herceptin	19	-36	15	-30	13	-27	12	-28	11	-28
Avastin	172	0	131	-12	132	-13	115	-19	112	-21
Kadcyla	36	42	32	28	36	20	33	16	30	2
MabThera/Rituxan	11	-17	8	-15	9	-2	7	-13	8	-23
Ronapreve	285	-	483	-	-16**	-	-15**	-100	1,028	313
Alecensa	66	5	54	7	60	5	55	4	59	7
Activase/TNKase	-	-	-	-	-	-	-	-	-	-
Evrysdi	16	-	17	-	21	-	22	*	24	83
Lucentis	-	-	-	-	-	-	-	-	-	-
Phesgo	-	-	-	-	-	-	-	-	-	-
Gazyva	15	-7	15	8	13	-10	11	-17	11	-12
Esbriet	-	-	-	-	-	-	-	-	-	-
Vabysmo	-	-	-	-	7	-	17	-	23	-
Pulmozyme	1	22	-	-	-	-	-	-	1	38

* Over 500%

**Effect of currency revaluation (CHF/JPY) on CHF483mn Q1 2022 Ronapreve sales

8. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth International*

CHF millions	Q4 2021	% change vs. Q4 2020	Q1 2022	% change vs. Q1 2021	Q2 2022	% change vs. Q2 2021	Q3 2022	% change vs. Q3 2021	Q4 2022	% change vs. Q4 2021
Ocrevus	109	51	119	29	112	62	105	26	138	29
Perjeta	311	24	344	32	400	37	375	30	330	13
Hemlibra	78	55	79	63	109	115	87	53	114	45
Tecentriq	98	24	89	0	117	17	136	30	163	70
Actemra/RoActemra	62	-55	105	-30	92	-44	70	-44	94	51
Xolair	-	-	-	-	-	-	-	-	-	-
Herceptin	342	17	326	-18	329	-3	272	-22	266	-17
Avastin	233	-24	214	-23	207	-17	198	-23	186	-16
Kadcyla	107	38	103	26	138	81	121	46	96	-3
MabThera/Rituxan	166	-15	155	-23	149	-13	110	-32	109	-28
Ronapreve	102	-	42	-	35	-68	-	-	21	-81
Alecensa	123	25	133	45	142	29	134	9	131	13
Activase/TNKase	15	7	13	-3	15	4	17	12	18	20
Evrysdi	42	**	32	**	51	-5	49	231	80	73
Lucentis	-	-	-	-	-	-	-	-	-	-
Phesgo	3	**	10	**	14	278	22	20	23	**
Gazyva	25	56	29	75	36	101	40	91	38	62
Esbriet	7	-36	9	-36	8	-36	6	109	6	13
Vabysmo	-	-	-	-	1	-	-	-	4	-
Pulmozyme	22	45	23	-4	21	14	17	-16	16	-9

* Asia-Pacific, CEETRIS (Central Eastern Europe, Türkiye, Russia and Indian Sub-Continent), Latin America, Middle East, Africa, Canada, others

** Over 500%

9. Roche Group consolidated income statement for the twelve months ended 31 December 2022

in millions of CHF	Pharma- ceuticals	Diagnostics	Corporate	Group
Sales	45,551	17,730	-	63,281
Royalties and other operating income	3,077	68	-	3,145
Cost of sales	(11,397)	(9,000)	-	(20,397)
Marketing and distribution	(6,725)	(2,914)	-	(9,639)
Research and development	(14,060)	(1,963)	-	(16,023)
General and administration	(1,632)	(597)	(662)	(2,891)
Operating profit	14,814	3,324	(662)	17,476
Financing costs				(665)
Other financial income (expense)				(484)
Profit before taxes				16,327
Income taxes				(2,796)
Net income				13,531
Attributable to				
- Roche shareholders				12,421
- Non-controlling interests				1,110
Earnings per share and non-voting equity security				
Basic (CHF)				15.52
Diluted (CHF)				15.37

10. Roche Group core results reconciliation – Full Year 2022

in millions of CHF	IFRS	Global restructuring	Intangibles amortisation	Intangibles impairment	Mergers and acquisitions and alliance transactions	Legal & environmental	Pension plan settlements	Global issues	Normalisation of ECP tax benefit	Core
Sales	63,281	-	-	-	-	-	-	-	-	63,281
Royalties and other operating income	3,145	-	-	-	-	-	-	-	-	3,145
Cost of sales	(20,397)	295	555	1,472	-	-	-	-	-	(18,075)
Marketing and distribution	(9,639)	59	34	-	-	-	-	-	-	(9,546)
Research and development	(16,023)	261	344	1,365	-	-	-	-	-	(14,053)
General and administration	(2,891)	354	-	-	(20)	(22)	-	-	-	(2,579)
Operating profit	17,476	969	933	2,837	(20)	(22)	-	-	-	22,173
Financing costs	(665)	-	-	-	(1)	(20)	-	-	-	(686)
Other financial income (expense)	(484)	-	-	-	(44)	-	-	-	-	(528)
Profit before taxes	16,327	969	933	2,837	(65)	(42)	-	-	-	20,959
Income taxes	(2,796)	(193)	(80)	(435)	(1)	8	-	-	68	(3,429)
Net income	13,531	776	853	2,402	(66)	(34)	-	-	68	17,530
Attributable to										
- Roche shareholders	12,421	761	849	2,402	(66)	(34)	-	-	68	16,401
- Non- controlling interests	1,110	15	4	-	-	-	-	-	-	1,129
EPS - diluted (CHF)	15.37	0.94	1.05	2.98	(0.08)	(0.04)	-	-	0.08	20.30

11. Divisional core results reconciliation – Full Year 2022

in millions of CHF

	IFRS	Global restructuring	Intangibles amortisation	Intangibles impairment	Mergers and acquisitions and alliance transactions	Legal & environmental	Pension plan settlements	Core
Pharmaceuticals								
Sales	45,551	-	-	-	-	-	-	45,551
Royalties and other operating income	3,077	-	-	-	-	-	-	3,077
Cost of sales	(11,397)	251	412	1,472	-	-	-	(9,262)
Marketing and distribution	(6,725)	55	13	-	-	-	-	(6,657)
Research and development	(14,060)	263	336	1,365	-	-	-	(12,096)
General and administration	(1,632)	213	-	-	(6)	(16)	-	(1,441)
Operating profit	14,814	782	761	2,837	(6)	(16)	-	19,172
Diagnostics								
Sales	17,730	-	-	-	-	-	-	17,730
Royalties and other operating income	68	-	-	-	-	-	-	68
Cost of sales	(9,000)	44	143	-	-	-	-	(8,813)
Marketing and distribution	(2,914)	4	21	-	-	-	-	(2,889)
Research and development	(1,963)	(2)	8	-	-	-	-	(1,957)
General and administration	(597)	30	-	-	(14)	(2)	-	(583)
Operating profit	3,324	76	172	-	(14)	(2)	-	3,556
Corporate								
General and administration	(662)	111	-	-	-	(4)	-	(555)
Operating profit	(662)	111	-	-	-	(4)	-	(555)

12. Roche Group consolidated balance sheet

in millions of CHF	31 December 2022	31 December 2021	31 December 2020
Non-current assets			
Property, plant and equipment	23,075	23,163	22,158
Right-of-use assets	1,133	1,249	1,112
Goodwill	10,820	10,809	9,249
Intangible assets	9,685	12,117	12,017
Deferred tax assets	6,427	5,583	5,459
Defined benefit plan assets	957	1,498	967
Other non-current assets	2,238	2,271	2,234
Total non-current assets	54,335	56,690	53,196
Current assets			
Inventories	8,605	7,715	7,194
Accounts receivable	11,606	10,806	10,154
Current income tax assets	313	320	149
Other current assets	3,525	3,755	3,111
Marketable securities	4,776	6,181	6,607
Cash and cash equivalents	4,991	6,850	5,727
Total current assets	33,816	35,627	32,942
Total assets	88,151	92,317	86,138
Non-current liabilities			
Long-term debt	(21,391)	(16,076)	(10,220)
Net deferred tax liabilities	(645)	(628)	(353)
Defined benefit plan liabilities	(4,561)	(6,103)	(7,831)
Provisions	(1,111)	(1,442)	(1,453)
Other non-current liabilities	(1,189)	(1,307)	(1,107)
Total non-current liabilities	(28,897)	(25,556)	(20,964)
Current liabilities			
Short-term debt	(3,960)	(15,122)	(3,996)
Current income tax liabilities	(3,187)	(3,002)	(3,679)
Provisions	(2,248)	(2,526)	(1,836)
Accounts payable	(4,556)	(4,637)	(4,121)
Other current liabilities	(13,288)	(13,129)	(11,769)
Total current liabilities	(27,239)	(38,416)	(25,401)
Total liabilities	(56,136)	(63,972)	(46,365)
Total net assets	32,015	28,345	39,773
Equity			
Capital and reserves attributable to Roche shareholders	27,992	24,489	36,341
Equity attributable to non-controlling interests	4,023	3,856	3,432
Total equity	32,015	28,345	39,773

13. Roche Group consolidated statement of cash flows

in millions of CHF	FY 2022	FY 2021
Cash flows from operating activities		
Cash generated from operations	26,030	26,600
(Increase) decrease in net working capital	(2,418)	(994)
Payments made for defined benefit plans	(655)	(619)
Utilisation of provisions	(1,052)	(1,166)
Disposal of products	612	496
Other operating cash flows	-	2
Cash flows from operating activities, before income taxes paid	22,517	24,319
Income taxes paid	(4,102)	(3,343)
Total cash flows from operating activities	18,415	20,976
Cash flows from investing activities		
Purchase of property, plant and equipment	(3,449)	(3,693)
Purchase of intangible assets	(1,103)	(856)
Disposal of property, plant and equipment	82	61
Disposal of intangible assets	-	-
Business combinations	(245)	(2,361)
Divestment of subsidiaries	1	7
Interest and dividends received	32	(2)
Sales of marketable securities	148	235
Purchases of marketable securities	(271)	(201)
Sales (purchases) of money market instruments and time accounts over three months, net	1,250	329
Other investing cash flows	19	(71)
Total cash flows from investing activities	(3,536)	(6,552)
Cash flows from financing activities		
Proceeds from issue of bonds and notes	8,442	6,900
Redemption and repurchase of bonds and notes	(1,750)	(2,448)
Increase (decrease) in commercial paper	1,293	(1,134)
Increase (decrease) in other debt	(13,683)	13,412
Hedging and collateral arrangements	(526)	(522)
Changes in ownership interests in subsidiaries	-	-
Changes in non-controlling interests	-	-
Equity contribution by non-controlling interests - capital injection	-	-
Interest paid	(557)	(405)
Principal portion of lease liabilities paid	(405)	(382)
Dividends paid	(7,832)	(8,132)
Equity-settled equity compensation plans, net of transactions in own equity	(1,257)	(20,397)
Other financing cash flows	-	-
Total cash flows from financing activities	(16,275)	(13,108)
Net effect of currency translation on cash and cash equivalents	(463)	(193)
Increase (decrease) in cash and cash equivalents	(1,859)	1,123
Cash and cash equivalents at beginning of period	6,850	5,727
Cash and cash equivalents at end of period	4,991	6,850